Correction: RSF1 is a positive regulator of NFκB-induced gene expression required for ovarian cancer chemoresistance (Cancer Research (2014) 74 (3615-3624) DOI: 10.1158/0008-5472.CAN-13-2459);RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2258-2269

  Yang, Yeong In ^a   Ahn, Ji Hye ^a   Lee, Kyung Tae ^a   Shih, Ie Ming ^b   Choi, Jung Hye ^a  

^a Kyung Hee University   (South Korea)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN BCL 2; SHORT HAIRPIN RNA; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCL 2 GENE; BCL2L1 GENE; CANCER CELL; CANCER RESISTANCE; CFLAR GENE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; PTGS2 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RSF1 GENE; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; XIAP GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN BINDING; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899567055     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-2556     Document Type: Erratum

References (48)

1. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
2. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, et al. A BTB/POZ gene, NAC-1, a tumor recurrence-Associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 2008;14:3149-55.
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
4. Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YT, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem 2010;285:38260-9.
5. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 2005;102:14004-9.
6. Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, et al. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol 2006;37:1169-75.
7. Chen TJ, Huang SC, Huang HY, Wei YC, Li CF. Rsf-1/HBXAP overexpression is associated with disease-specific survival of patientswith gallbladder carcinoma. APMIS 2011;119:808-14.
8. Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol 2011;178:2407-15.
9. Li Q, Dong Q, Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun 2012;420:6-10.
10. Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol 2012;33: 1485-91.
11. Tai HC, Huang HY, Lee SW, Lin CY, Sheu MJ, Chang SL, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol 2012;65:248-53.
12. Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, et al. Rsf-1/ HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma. J Clin Pathol 2012;65:802-7.
13. Sheu JJ, Choi JH, Yildiz I, Tsai FJ, Shaul Y, Wang TL, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumorpromoting functions of Rsf-1. Cancer Res 2008;68:4050-7.
14. Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 2006;103:814-9.
15. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 2009;69:1407-15.
16. Loyola A, Huang JY, LeRoy G, Hu S, Wang YH, Donnelly RJ, et al. Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol 2003;23:6759-68.
17. Shamay M, Barak O, Doitsh G, Ben-Dor I, Shaul Y. Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription. J Biol Chem 2002;277:9982-8.
18. Huang JY, Shen BJ, Tsai WH, Lee SC. Functional interaction between nuclear matrix-AssociatedHBXAP andNF-kappaB. Exp Cell Res 2004; 298:133-43.
19. Shamay M, Barak O, Shaul Y. HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics 2002;79:523-9.
20. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
21. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NFkappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.
22. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NFkappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7.
23. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
24. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, et al. Oncoproteomic analysis reveals coupregulation of RELA and STAT5 in carboplatin-resistant ovarian carcinoma. PLoS ONE 2010;5:e11198.
25. Wang W, Cassidy J. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 2003; 88:624-9.
26. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006; 25:6800-16.
27. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004;10:7645-54.
28. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003;1:66.
29. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
30. Kim SH, Juhnn YS, Song YS. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann Ny Acad Sci 2007;1095: 82-9.
31. Huang Y, Fan W. IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 2002;61:105-13.
32. Yang YI, Lee KT, Park HJ, Kim TJ,Choi YS, Shih Ie M, et al. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway. Carcinogenesis 2012;33:2488-98.
33. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves downregulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005;280:6301-8.
34. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002;4:993-7.
35. Arts HJ, Van Der Zee AG, De Jong S, De Vries EG. Options for modulation of drug resistance in ovarian cancer. Int J Gynecol Cancer 2000;10:47-52.
36. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
37. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
38. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-66.
39. Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH. TCRmediated upregulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J Immunol 2000;165:6293-300.
40. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NFkappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281: 1680-3.
41. Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999;35:1374-80.
42. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 2004;68:1145-55.
43. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREBbinding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 1997;94:2927-32.
44. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661-71.
45. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 2009;284:2657-71.
46. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, et al. Integrin alpha4 blockade sensitizes drug-resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood 2013;121: 1814-8.
47. Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, et al. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Biomed Pharmacother 2009;63:553-60.
48. Dubey R, Levin MD, Szabo LZ, Laszlo CF, Kushal S, Singh JB, et al. Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex. J Am Chem Soc 2013;135:4537-49.